Filtros de búsqueda

Lista de obras de

30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement

artículo científico publicado en 2009

A Call for Open-Source Cost-Effectiveness Analysis

artículo científico publicado en 2017

A Call for Open-Source Cost-Effectiveness Analysis

artículo científico publicado en 2018

A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures

scientific article published on 06 December 2017

A Flexible Approach To Evidentiary Standards For Comparative Effectiveness Research ⬇️

artículo científico publicado el 1 de octubre de 2010

A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1]

artículo científico publicado en 2018

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

artículo científico publicado en 2018

A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients.

artículo científico publicado en 2017

A Review of Empirical Analyses of Disinvestment Initiatives

artículo científico publicado en 2017

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted

artículo científico publicado en 2016

A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006.

artículo científico publicado en 2010

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline

artículo científico publicado en 2016

A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness research

artículo científico publicado en 2011

A model of the economic impact of a bipolar disorder screening program in primary care

artículo científico publicado en 2009

A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy

scientific article published on October 2011

A role for research: an observation on preventive services for women

artículo científico publicado en 2013

A strategic plan for integrating cost-effectiveness analysis into the US healthcare system.

artículo científico

A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics

artículo científico publicado en 2013

A synthesis of cost-utility analysis literature in infectious disease

artículo científico publicado en 2005

Accelerating Alzheimer's disease drug innovations from the research pipeline to patients.

artículo científico publicado en 2018

Adherence to the iDSI reference case among published cost-per-DALY averted studies

scientific article published on 01 May 2019

Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit

artículo científico publicado en 2012

An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]

scientific article published on 01 February 2018

Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy

scientific article published on 17 May 2019

Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social Consequences

scientific article published on 01 April 2020

Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?

artículo científico publicado en 2010

Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study

artículo científico publicado en 2016

Bias in published cost effectiveness studies: systematic review

artículo científico publicado en 2006

Biotechnology and Medicare's new technology policy: lessons from three case studies

artículo científico publicado en 2006

CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY.

artículo científico publicado en 2016

Can We Better Prioritize Resources for Cost-Utility Research?

artículo científico publicado en 2005

Can we reliably benchmark health technology assessment organizations?

artículo científico publicado en 2012

Cancer therapy costs influence treatment: a national survey of oncologists

scientific article published on 01 January 2010

Challenges with Forecasting Budget Impact: A Case Study of Six ICER Reports

scientific article published on 14 December 2018

Communicating and promoting comparative-effectiveness research findings

artículo científico publicado en 2013

Comparative Modeling to Inform Health Policy Decisions: A Step Forward

scientific article published on 05 November 2019

Comparative effectiveness research panel at the 2012 Advertising & Promotion Conference of the Food & Drug Law Institute

artículo científico publicado en 2012

Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures

Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs

artículo científico publicado en 2010

Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics Authors

scientific article published on 01 November 2019

Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions

artículo científico publicado en 2018

Cost effectiveness of topiramate in the prevention of migraines in the United States: an update

artículo científico publicado en 2006

Cost savings and cost-effectiveness of clinical preventive care

artículo científico publicado en 2009

Cost-Effectiveness Analysis 2.0.

artículo científico publicado en 2017

Cost-Effectiveness Analysis Expands its Reach Worldwide

artículo científico publicado en 2016

Cost-Effectiveness Analysis in Pediatric Imaging: The Evidence (or Lack Thereof) Thus Far

artículo científico publicado en 2019

Cost-Effectiveness Studies in the ICU: A Systematic Review

scientific article published on 01 August 2019

Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?

artículo científico publicado en 2010

Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives

artículo científico publicado en 2018

Cost-effectiveness of PET in the diagnosis of Alzheimer disease.

artículo científico publicado en 2003

Cost-effectiveness of adherence-enhancing interventions: a systematic review.

artículo científico publicado en 2016

Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment

artículo científico publicado en 2005

Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence

artículo científico

Cost-utility analyses in orthopaedic surgery

artículo científico publicado en 2005

Cost-utility analyses of diagnostic laboratory tests: a systematic review

artículo científico publicado en 2011

Cost-utility analysis studies of depression management: a systematic review

artículo científico publicado en 2004

Costing and perspective in published cost-effectiveness analysis

artículo científico publicado en 2009

Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans

artículo científico publicado en 2020

Cross-national comparison of technology assessment processes

artículo científico publicado en 2004

Decision analytic models for Alzheimer's disease: state of the art and future directions.

artículo científico publicado en 2008

Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis

artículo científico publicado en 2004

Dependence as a unifying construct in defining Alzheimer's disease severity

artículo científico publicado en 2010

Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs

artículo científico publicado en 2014

Development and validation of a grading system for the quality of cost-effectiveness studies

artículo científico publicado en 2003

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Medical Economic Perspective

artículo científico publicado en 2007

Diffusion of published cost-utility analyses in the field of health policy and practice

artículo científico publicado en 2005

Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies

artículo científico publicado en 2018

Do drug formulary policies reflect evidence of value?

artículo científico publicado en 2006

Does Medicare have an implicit cost-effectiveness threshold?

artículo científico publicado en 2010

Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?

artículo científico publicado en 2011

Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents

artículo científico publicado en 2013

Does preventive care save money? Health economics and the presidential candidates

artículo científico publicado en 2008

Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?

scientific article published on 07 October 2019

Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process.

artículo científico publicado en 2017

EBM, HTA, and CER: clearing the confusion

artículo científico publicado en 2010

Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients.

artículo científico publicado en 2017

Economic evaluation in the US: what is the missing link?

artículo científico publicado en 2006

Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States

artículo científico

Economic messages in prescription drug advertisements in medical journals

artículo científico publicado en 2002

Embracing the science of value in health

scientific article published on 01 July 2019

Emerging lessons from the drug effectiveness review project

artículo científico publicado en 2006

Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval

artículo científico publicado en 2016

FDA actions against health economic promotions, 2002-2011.

artículo científico publicado en 2012

FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation

artículo científico publicado en 2002

Factors predicting Medicare national coverage: an empirical analysis.

artículo científico publicado en 2012

Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions

scientific article published on 01 April 2019

Future Directions for Cost-effectiveness Analyses in Health and Medicine

article

Growth and capacity for cost-effectiveness analysis in Africa

artículo científico publicado en 2020

Growth and quality of the cost-utility literature, 1976-2001.

artículo científico publicado en 2005

Health Economics Tools and Precision Medicine: Opportunities and Challenges

artículo científico publicado en 2020

Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis

artículo científico publicado en 2005

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia

article

Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease

artículo científico publicado en 2017

How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments

artículo científico publicado en 2010

How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?

artículo científico publicado en 2004

ICER's Revised Value Assessment Framework for 2017-2019: A Critique

scientific article published on 01 October 2017

Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures

artículo científico publicado en 2013

Impact of referral patterns on the use of chemotherapy for lung cancer.

artículo científico publicado en 2002

Imputing productivity gains from clinical trials

artículo científico publicado en 2012

In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival

artículo científico publicado en 2012

Insurance coverage for genomic tests.

artículo científico publicado en 2018

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework

scientific article published on 13 June 2016

Is the United States ready for QALYs?

artículo científico publicado en 2009

Key principles for the improved conduct of health technology assessments for resource allocation decisions

artículo científico publicado en 2008

Lack of Cost-Effectiveness Analyses to Address Healthy People 2020 Priority Areas.

artículo científico publicado en 2016

Legislating against Use of Cost-Effectiveness Information ⬇️

artículo científico publicado el 14 de octubre de 2010

Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers

scientific article published on 11 March 2010

Listening to Provenge — What a Costly Cancer Treatment Says about Future Medicare Policy ⬇️

artículo científico publicado el 6 de abril de 2011

Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage

scientific article published on 01 November 2019

Long-term persistence in use of statin therapy in elderly patients

artículo científico publicado en 2002

Low-value services in value-based insurance design.

artículo científico publicado en 2010

Mapping US commercial payers' coverage policies for medical interventions

artículo científico publicado en 2016

Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS.

artículo científico publicado en 2012

Measuring the Value of Prescription Drugs

artículo científico publicado en 2015

Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis

artículo científico publicado en 2016

Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations

article

Medicare and cost-effectiveness analysis

artículo científico publicado en 2005

Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain

artículo científico publicado en 2013

Medicare's Interventions Coverage: The Authors Reply

scientific article published on 01 June 2015

Medicare's enduring struggle to define "reasonable and necessary" care

artículo científico publicado en 2012

Medicare's national coverage decisions for technologies, 1999-2007.

artículo científico publicado en 2008

Medicare's national coverage determinations in diagnostic radiology: examining evidence and setting limits

artículo científico publicado en 2012

Medicare's use of cost-effectiveness analysis for prevention (but not for treatment).

artículo científico publicado en 2014

Migraine frequency and health utilities: findings from a multisite survey

artículo científico publicado en 2008

Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care

artículo científico publicado en 2013

Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs

scientific article published on 13 April 2020

Outcome measures for oncology alternative payment models: practical considerations and recommendations

artículo científico publicado en 2019

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value

artículo científico publicado en 2018

Patient Variability Seldom Assessed in Cost-Effectiveness Studies.

artículo científico publicado en 2018

Patient adherence: a blind spot in cost-effectiveness analyses?

artículo científico publicado en 2009

Patients' willingness to pay for autologous blood donation

Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk

artículo científico publicado en 2016

Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018

artículo científico publicado en 2020

Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer’s disease and related disorders

scientific article published on 01 January 2013

Prevention of non-communicable disease: best buys, wasted buys, and contestable buys

scientific article published on 28 January 2020

Price and value in cancer care

artículo científico publicado en 2015

Principles for planning and conducting comparative effectiveness research.

artículo científico

Private payers disagree with Medicare over medical device coverage about half the time

artículo científico

Private sector risk-sharing agreements in the United States: trends, barriers, and prospects

artículo científico publicado en 2015

Publication of Decision Model Source Code: Attitudes of Health Economics Authors

scientific article published on 01 November 2019

QALYs in 2018-Advantages and Concerns

scientific article published on 01 June 2018

Quality of abstracts of papers reporting original cost-effectiveness analyses

artículo científico publicado en 2005

Quality of clinical and economic evidence in dossier formulary submissions

artículo científico publicado en 2007

Racial and Ethnic Differences in Knowledge About One's Dementia Status

scientific article published on 13 April 2020

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine

artículo científico publicado en 2016

Recommendations on Perspectives for the Reference Case

Reducing cardiovascular disease: opportunities and consequences

artículo científico publicado en 2008

Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy

artículo científico publicado en 2019

Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS.

artículo científico publicado en 2011

Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus

artículo científico publicado en 2010

Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].

artículo científico publicado en 2018

Risk-Targeted Lung Cancer Screening

artículo científico publicado en 2018

Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis

artículo científico publicado en 2018

Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement

artículo científico

Specialty Drug Coverage Varies Across Commercial Health Plans In The US

scientific article published on 01 July 2018

Taking stock of cost-effectiveness analysis of healthcare in China.

artículo científico publicado en 2019

Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency

artículo científico publicado en 2019

The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients

artículo científico publicado en 2016

The Potential Value of β-Amyloid Imaging for the Diagnosis and Management of Dementia: A Survey of Clinicians

artículo científico publicado en 2016

The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study

artículo científico publicado en 2014

The Role of Decision Models in Health Care Policy: A Case Study.

artículo científico publicado en 2016

The State of Cost-Utility Analyses in Asia: A Systematic Review

scientific article published on 24 March 2015

The adoption of cost-effectiveness acceptability curves in cost-utility analyses

artículo científico publicado en 2009

The changing face of the cost-utility literature, 1990-2012.

artículo científico publicado en 2015

The cost-effectiveness of biopharmaceuticals: a look at the evidence

artículo científico publicado en 2012

The economic burden of intracerebral hemorrhage: evidence from managed care.

artículo científico publicado en 2006

The economics of mild cognitive impairment

artículo científico publicado en 2012

The impact of formulary drug exclusion policies on patients and healthcare costs

artículo científico publicado en 2016

The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh.

artículo científico publicado en 2016

The influence of time horizon on results of cost-effectiveness analyses

artículo científico

The lag from FDA approval to published cost-utility evidence

artículo científico publicado en 2015

The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology

artículo científico publicado en 2015

The validity of dependence as a health outcome measure in Alzheimer's disease

artículo científico publicado en 2013

The value of specialty pharmaceuticals - a systematic review

artículo científico

Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries

artículo científico

Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks

artículo científico publicado en 2017

Trends in cost effectiveness analyses in orthopaedic surgery

artículo científico publicado en 2007

Trends in the measurement of health utilities in published cost-utility analyses

artículo científico publicado en 2006

Twenty years of cost-effectiveness analysis in medical imaging: are we improving?

artículo científico publicado en 2008

US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research

artículo científico publicado en 2011

US healthcare reform: implications for health economics and outcomes research

artículo científico publicado en 2010

Understanding and improving value frameworks with real-world patient outcomes

scientific article published on 01 November 2018

Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models

artículo científico publicado en 2017

Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease

artículo científico publicado en 2014

Updated Recommendations for Cost-effectiveness Studies-Reply.

artículo científico publicado en 2017

Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold

artículo científico publicado en 2014

Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies

artículo científico publicado en 2018

Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making

artículo científico publicado en 2003

Using Cost-Effectiveness Analysis in Health and Medicine

article

Using Decision Analysis To Better Evaluate Pediatric Clinical Guidelines

artículo científico publicado en 2008

Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?

scientific article published on 28 April 2020

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

artículo científico publicado en 2007

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.

artículo científico publicado en 2015

Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the US.

artículo científico publicado en 2007

Variation in US private health plans' coverage of orphan drugs

artículo científico publicado en 2019

What can we learn from the U.S. expanded end-stage renal disease bundle?

scientific article published on 16 February 2013

What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits)

artículo científico publicado en 2007

When Does FDAMA Section 114 Apply? Ten Case Studies

artículo científico publicado en 2015

When Is Evidence Sufficient?

article

When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs.

artículo científico publicado en 2017

When does quality-adjusting life-years matter in cost-effectiveness analysis?

artículo científico publicado en 2004

When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology ⬇️

artículo científico publicado en 2010

When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature

artículo científico publicado en 2006

Where are we on "risk-sharing" agreements?

artículo científico publicado en 2013

Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions

artículo científico publicado en 2013

Why don't Americans use cost-effectiveness analysis?

artículo científico publicado en 2004

Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study

artículo científico publicado en 2004

Willingness to pay for diagnostic technologies: a review of the contingent valuation literature

artículo científico

Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents

artículo científico publicado en 2010

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda